Detection of Circulating Tumor Cells in Breast Cancer Patients: Prognostic Predictive Role

Turker, Ibrahim; Uyeturk, Ummugul; Sonmez, Ozlem Uysal; Oksuzoglu, Berna; Helvaci, Kaan; Arslan, Ulku Yalcintas; Budakoglu, Burcin; Alkis, Necati; Aksoy, Sercan; Zengin, Nurullah

추천

검색

자료유형: 학술저널

저자정보: Turker, Ibrahim (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Uyeturk, Ummugul (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Sonmez, Ozlem Uysal (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Oksuzoglu, Berna (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Helvaci, Kaan (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Arslan, Ulku Yalcintas (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Budakoglu, Burcin (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Alkis, Necati (Medical Oncology Department, Ankara Oncology Training and Research Hospital) Aksoy, Sercan (Medical Oncology Department, Ankara Numune Training and Research Hospital) Zengin, Nurullah (Medical Oncology Department, Ankara Numune Training and Research Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제3호

발행연도: 2013.1

수록면: 1,601 - 1,607 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

A determination of circulating tumor cell (CTC) effectiveness for prediction of progression-free survival (PFS) and overall survival (OS) was conducted as an adjunct to standard treatment of care in breast cancer management. Between November 2008 and March 2009, 22 metastatic and 12 early stage breast carcinoma patients, admitted to Ankara Oncology Training and Research Hospital, were included in this prospective trial. Patients' characteristics, treatment schedules and survival data were evaluated. CTC was detected twice by CellSearch method before and 9-12 weeks after the initiation of chemotherapy. A cut-off value equal or greater than 5 cells per 7.5 ml blood sample was considered positive. All patients were female. Median ages were 48.0 (range: 29-65) and 52.5 (range: 35-66) in early stage and metastatic subgroups, respectively. CTC was positive in 3 (13.6%) patients before chemotherapy and 6 (27.3%) patients during chemotherapy in the metastatic subgroup whereas positive in only one patient in the early stage subgroup before and during chemotherapy. The median follow-up was 22.0 (range: 21-23) and 19.0 (range: 5-23) months in the early stage and metastatic groups, respectively. In the metastatic group, both median PFS and OS were significantly shorter in any time CTC positive patients compared to CTC negative patients (PFS: 4.0 vs 14.0 months, Log-Rank p=0.013; and OS: 8.0 months vs. 20.5 months, Log-Rank p<0.001). OS was affected from multiple visceral metastatic sites (p=0.055) and higher grade (p=0.044) besides CTC positivity (log rank p<0.001). Radiological response of chemotherapy was also correlated with better survival (p<0.001). As a result, CTC positivity was confirmed as a prospective marker even in a small patient population, in this single center study. Measurement of CTC by CellSearch method in metastatic breast carcinoma cases may allow indications of early risk of relapse or death with even as few as two measurements during a chemotherapy program, but this finding should be confirmed with prospective trials in larger study populations.

#Breast cancer #circulating tumor cells #survival

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요